Qubit Pharmaceuticals selected as one of the 100 Technology Pioneers 2024 by the World Economic Forum
06 juin 2024 03h00 HE
|
Qubit Pharmaceuticals
Press release Qubit Pharmaceuticals selected as one of the 100 Technology Pioneers 2024 by the World Economic Forum Qubit Pharmaceuticals joins the prestigious community of 100 disruptive...
HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)
28 mai 2024 08h00 HE
|
HiberCell, Inc.
HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial in AML, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine
HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366
05 avr. 2024 10h00 HE
|
HiberCell, Inc.
HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa
27 mars 2024 08h00 HE
|
Vector Pharma FZCO; Oncopeptides AB
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa
High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer therapies
30 janv. 2024 02h30 HE
|
Qubit Pharmaceuticals
Press Release High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer...
PR : Iktos and Nerviano Medical Sciences S.r.l Announce Collaboration in Artificial Intelligence for New Drug Discovery
08 janv. 2024 02h00 HE
|
ULYSSE COMMUNICATION
Iktos and Nerviano Medical Sciences S.r.l Announce Collaboration in Artificial Intelligence for New Drug Discovery Paris, France, 8 January, 2023 – Iktos, a company specialized in Artificial...
Syapse and FDA Extend Collaboration to Advance the Use of Real-World Data (RWD) and Inform Regulatory Science in Oncology
05 déc. 2023 12h26 HE
|
Syapse
Research collaboration between Syapse and the FDA Oncology Center of Excellence extended to assess fit-for-purpose RWD and explore the potential of RWE.
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
08 nov. 2023 07h30 HE
|
HCW Biologics, Inc
Preliminary data readout from a Phase 1 study to evaluate HCW9218, the lead drug candidate of HCW Biologics, in solid tumors.
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
06 sept. 2023 07h30 HE
|
HCW Biologics, Inc
MIRAMAR, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan
27 avr. 2023 07h40 HE
|
HCW Biologics, Inc
Provides funding for buildout of new headquarters and manufacturing facility Capital requirements now funded into 2025 MIRAMAR, Fla., April 27, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the...